On July 31, 2019 Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, reported that Kevin Hrusovsky, Chief Executive Officer, President and Chairman of Quanterix, will present at the Canaccord Genuity 39th Annual Growth Conference, on Wednesday, Aug. 7, 2019 at 9:30 a.m., EDT at the InterContinental Boston (Press release, Quanterix, JUL 31, 2019, View Source [SID1234537957]). Hrusovsky, who will also share remarks at an investor dinner the prior evening hosted by Canaccord Genuity to discuss company momentum in advancing Alzheimer’s treatments and diagnoses, will also be available for one-on-one meetings during the conference.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"Our mission to disrupt the field of precision health has been fueled by recent product launches incorporating new technological innovations, expansion of our assay menu, greater scale and capabilities in our CLIA-certified Accelerator Service Lab, and most recently the strategic acquisition of UmanDiagnostics, which further accelerates our ability to expand the availability of Nf-L as a transformative biomarker for neurodegenerative diseases," said Hrusovsky. "These achievements demonstrate the impact of our disruptive innovation in the field of precision health, and we are excited to return to Canaccord Genuity this year to share greater insight into our growth trajectory, mission to revolutionize today’s healthcare system, and broad opportunity horizon for future value creation."
In addition to acquiring UmanDiagnostics AB and consolidating its operations in Billerica, Mass., Quanterix further solidified its position as a market leader through several recent critical milestones, including:
The expansion of Quanterix’ executive leadership team with top-tier commercial talent;
Unveiling of the Simoa HD-X Analyzer, which has already been placed with several early access customers;
Hosting of major Alzheimer’s Disease KOL dinner event at the 2019 Alzheimer’s Association International Convention;
Hrusovsky’s recognition as a 2019 Entrepreneur Of The Year in New England, one of the region’s highest business honors; and,
Completion of a nearly $50 million capital raise.
Hrusovsky will elaborate on these advances and share details regarding the Company’s unique growth strategy inside its product portfolio and commercial channel footprint.
To access the live webcast of Quanterix’ presentation, please visit the News & Events page within the investor relations section of the Quanterix website at www.quanterix.com. Replays of the webcast will be available for 90 days following the conference.